Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J agrees to Propulsid settlement

Executive Summary

A Johnson & Johnson Propulsid litigation settlement will become effective once 85% of the death claims agree to its terms, J&J's Janssen division announced Feb. 5. J&J will pay between $69.5 mil. and $90 mil., depending on how many plaintiffs enroll in the program. The federal multi-district litigation includes approximately 4,000 plaintiffs, 300 of whom are alleged to have died from use of the drug. J&J ceased marketing Propulsid (cisapride) in 2000; the gastrointestinal agent is currently available through a limited access program...

You may also be interested in...



QUOTED. 28 February 2020. Jubilee Brown.

Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.

Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine

The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.

Surging China Coronavirus Trials Prompt Tougher Criteria

A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules. 

UsernamePublicRestriction

Register

PS043304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel